Traffic Lights - Latest Updates

Last updated: 06/11/2019

Other updates on this site
Drug Name Classification Clinical Indication Comments
Alutard Bee venom ® (NEW) Black Preventative treatment for bee sting allergy

Not yet reviewed

Alutard Wasp venom ® (NEW) Black Preventative treatment for wasp sting allergy

Not yet reviewed

BROMOCRIPTINE (UPDATED) Amber Simple Hyperprolactinaemic disorders

Annual monitoring undertaken in secondary care Primary care should be aware of fibrotic reactions

BUDESONIDE M/R TABLETS (Cortiment®) (NEW) Amber Simple Ulcerative colitis

See formulary for place in therapy

BUROSUMAB (Crysvita®) (NEW) Black X-linked hypophosphataemia in children and young people

Not yet reviewed

CABERGOLINE (UPDATED) Amber Simple Hyperprolactinaemic disorders

Annual monitoring undertaken in secondary care Primary care should be aware of fibrotic reactions

DALTEPARIN (UPDATED) Green Thromboprophylaxis and Treatment of DVT & PE
DEKAS (UPDATED) Amber Simple Vitamin Supplement for paediatric and adult patients with cystic fibrosis
DEKAS VITAMINS (various formulations) (NEW) Black Depending on formulation, bariatric surgery or liver disease

Not yet reviewed

DEXMEDETOMIDINE (Dexdor®) (NEW) Red Sedation of intubated paediatric patients in an intensive care setting.
DOLUTEGRAVIR WITH LAMIVUDINE (Dovato®) (NEW) Black HIV

Not yet reviewed

DOXYLAMINE SUCCINATE AND PYRIDOXINE (Xonvea®) (NEW) Black Nausea and vomiting in pregnancy

Not yet reviewed

EMICIZUMAB (Hemlibra®) (UPDATED) Red Severe congenitial haemophilia A without factor VIII inhibitors
FLUOCINOLONE ACETONIDE INTRAVITRAL IMPLANT (Iluvien®) (NEW) Red Recurrent non-infectious uveitis

In line with NICE TA590

Implementation date 31st October 2019

GALCANEZUMAB (Emgality ®) (NEW) Black Migraine prophylaxis

Not yet reviewed

GANIRELIX ACETATE (Fyremadel®) (NEW) Red Prevention of premature luteinising hormone (LH) surges in women undergoing ovarian stimulation for IVF
GUSELKUMAB (UPDATED) Red Moderate to severe plaque psoriasis in adults

In line with NICE TA 521.

 

INSULIN GLARGINE / LIXISENATIDE (Suliqua®) (UPDATED) Black Type 2 Diabetes mellitus in combination with metformin

New formulation
Not yet reviewed

LETERMOVIR (Prevymis®) (NEW) Red Prevention of cytomegalovirus disease after a stem cell transplant

In line with NICE TA591

Implementation date 31st October 2019

LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (Levosert®) (UPDATED) Green Contraception or heavy menstrual bleeding
LUBIPROSTONE (UPDATED) Green Chronic refractory constipation

Discontinued in the UK for commercial reasons

MELATONIN (Colonis®) (NEW) Black Jet lag
MELATONIN M/R 1mg and 5mg tablets (Slenyto ®) (UPDATED) Black Treatment of insomnia not covered by the simple amber status
MELATONIN M/R 1mg and 5mg tablets (Slenyto®) (UPDATED) Amber Simple Insomnia for children aged 2-18 years with Autism Spectrum Disorder and or Smith-Magenis.

New patients only

PARATHYROID HORMONE (Natpar®) (UPDATED) Red Post-trial continuation of treatment of chronic hypoparathyroidism when standard therapy alone is inadequate.
PRASTERONE 6.5mg PESSARY (Intrarosa®) (NEW) Black Vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms

Not yet reviewed.

PRUCALOPRIDE (UPDATED) Green Chronic refractory constipation
RAVULIZUMAB (Ultomiris®) (NEW) Black Paroxysmal nocturnal haemoglobinuria

Not yet reviewed

RISANKIZUMAB (Skyrizi®) (UPDATED) Red Moderate to severe plaque psoriasis

In line with NICE TA596

RIVASTIGMINE (UPDATED) Amber Simple Alzheimer's disease

in line with NICE NG 97

Change in traffic light status from 1st October 2018

SIROLIMUS GEL (NEW) Red Angiofibromas associated with tuberous sclerosis complex
TESTOSTERONE GEL (Tostran ®) (NEW) Green Testosterone deficiency in menopausal women (unlicensed)

Tostran brand only. As per NG 23

TEZACAFTOR AND IVACAFTOR (Symkevi ®) (NEW) Red Cystic Fibrosis as part of the Symkevi managed access programme only
TOFACITINIB (NEW) Red Moderately to severely active ulcerative colitis

In line with NICE TA 547

Implementation date 28th February 2019

ULIPRISTAL ACETATE (Esmya ®) (UPDATED) Red Uterine fibroids

In line with MHRA alert August 2018 regarding risks of liver injury.

Other Updates on this Website

Recent documents from LMSG and TAS

Shortage of Megace® (194 KB)

We have been notified that there are supply problems with Megace® (megestrol acetate) tablets which is expected to last for 5-6 weeks.

Date added: 4th Jul 2019

About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more